Amedisys (NASDAQ:AMED – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They presently have a $101.00 price objective on the health services provider’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 3.06% from the company’s previous close.
A number of other research analysts have also recently commented on the company. William Blair cut Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $100.67.
Get Our Latest Analysis on Amedisys
Amedisys Price Performance
Amedisys (NASDAQ:AMED – Get Free Report) last issued its earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.00 EPS. Sell-side analysts forecast that Amedisys will post 4.57 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of AMED. Water Island Capital LLC raised its position in Amedisys by 185.0% during the 4th quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock worth $67,559,000 after purchasing an additional 461,368 shares during the last quarter. Norges Bank bought a new position in Amedisys during the 4th quarter worth $34,032,000. Segantii Capital Management Ltd bought a new position in Amedisys during the 4th quarter worth $32,776,000. Calamos Advisors LLC bought a new position in Amedisys during the 4th quarter worth $23,015,000. Finally, Alpine Associates Management Inc. raised its position in Amedisys by 23.0% during the 4th quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider’s stock worth $120,830,000 after purchasing an additional 237,600 shares during the last quarter. 94.36% of the stock is owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Read More
- Five stocks we like better than Amedisys
- Why Invest in 5G? How to Invest in 5G Stocks
- Beauty Retailer Stock Brings Early Christmas for Value Investors
- Trading Halts Explained
- Ford Stock EPS Disappoints, Shares Plummet After-Hours
- Health Care Stocks Explained: Why You Might Want to Invest
- How Much Should You Be Investing? Try Our Calculators
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.